MARKERS FOR DETECTION OF GASTRIC CANCER – 20120135881

Abstract

Early detection of tumors is a major determinant of survival of patients suffering from tumors, including gastric tumors. Members of the GTM gene family can be differentially expressed in gastric tumor tissue, and thus can be used as markers for the detection of gastric and other types of cancer. The present invention provides for novel GTMs for the detection of tumors, including gastric tumors, and in particular human zymogen granule protein 16 (ZG16). The GTMs can be used in isolation or together with other known GTMs to provide for novel signatures to be used in the detection of tumors, including gastric tumors.
Continue reading “MARKERS FOR DETECTION OF GASTRIC CANCER – 20120135881”

METHOD FOR DETECTION OF, OR THE RISK OF, BLADDER CANCER – 20120135886

Abstract

The present invention provides a method for the detection of or the risk of bladder cancer in a patient, comprising the step of detecting the presence of a combination of at least two biomarkers selected from CEA, VEGF, IL-8, NGAL, NSE, IL-2, EGF, TM, d-Dimer, MMP-9, IL-6, IL-4, MMP-9/NGAL, FAS, CRP, TUP and NMP22 in one or more samples isolated from a patient wherein the presence of a combination of at least two biomarkers in the one or more samples indicates the presence or risk of bladder cancer.
Continue reading “METHOD FOR DETECTION OF, OR THE RISK OF, BLADDER CANCER – 20120135886”

METHOD FOR PREDICTING THE RESPONSE OF LOCALLY ADVANCED RECTAL CANCER TO CHEMORADIOTHERAPY – 20120135888

Abstract

The present invention relates to a method for determining or predicting the response of a patient diagnosed with locally advanced rectal cancer to chemoradiotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with rectal cancer to specific medicaments, radiotherapy and/or chemotherapy. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles in samples of said patients.
Continue reading “METHOD FOR PREDICTING THE RESPONSE OF LOCALLY ADVANCED RECTAL CANCER TO CHEMORADIOTHERAPY – 20120135888”

ANTIVIRAL TREATMENT OF LYMPHOMA AND CANCER – 20120135950

Abstract

Compositions and methods to treat lymphoma and cancer are disclosed. In particular, the method teaches treatment of lymphoma and cancer using anti-HERV-K(HML-2) therapies. Further taught are compositions and methods for characterizing patient samples to, for example, select or identify therapeutic options or assess the impact of therapies.
Continue reading “ANTIVIRAL TREATMENT OF LYMPHOMA AND CANCER – 20120135950”

IMMUNOLOGIC COMPOUNDS FOR PREVENTION, PROTECTION, PROPHYLAXIS OR TREATMENT OF IMMUNOLOGICAL DISORDERS, INFECTIONS AND CANCER – 20120136338

Abstract

The present invention provides for methods of treating a cancer patient. In one methods, cancer cells are harvested from a patient. A therapeutic amount of a rhodamine derivative is then added to the harvested cancer cells. The harvested cells and the rhodamine derivative are then irradiated with a suitable wavelength and intensity for the selective killing of the cancer cells. The irradiated cancer cells are then mixed with antigen presenting cells to form a mixture. The mixture of cancer and antigen presenting cells are then injected into the patient. The present invention also provides for methods of inhibiting or treating an immunological disorder, infection, or a cancer in an individual.
Continue reading “IMMUNOLOGIC COMPOUNDS FOR PREVENTION, PROTECTION, PROPHYLAXIS OR TREATMENT OF IMMUNOLOGICAL DISORDERS, INFECTIONS AND CANCER – 20120136338”

Anti-Mucin Antibodies for Early Detection and Treatment of Pancreatic Cancer – 20120141375

Abstract

Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to pancreatic cancer mucins such as MUC1 or MUC5ac and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay. Alternatively, immunoassay with PAM4 and anti-CA19.9 antibodies may be utilized to improve sensitivity for pancreatic cancer.
Continue reading “Anti-Mucin Antibodies for Early Detection and Treatment of Pancreatic Cancer – 20120141375”

PROSTATE SPECIFIC TRANSCRIPTS AND THE USE THEREOF FOR PROSTATE CANCER THERAPEUTICS AND DIAGNOSTICS – 20120141376

Abstract

Genes that are up regulated in human prostate tumor tissues and the corresponding proteins are identified. These genes and the corresponding antigens are suitable targets for the treatment, diagnosis or prophylaxis of prostate cancer.
Continue reading “PROSTATE SPECIFIC TRANSCRIPTS AND THE USE THEREOF FOR PROSTATE CANCER THERAPEUTICS AND DIAGNOSTICS – 20120141376”

Methods of Inhibiting Metastasis from Cancer – 20120141471

Abstract

The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX.sub.3CR1 or fractalkine antagonist.
Continue reading “Methods of Inhibiting Metastasis from Cancer – 20120141471”